Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06511531
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-06-22
Brief Title:
Exploring Sarcopenia in Parkinsons Disease Patients by Combining Serum Biomarker Levels
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinical Features and Possible Mechanisms in Patients With Sarcopenia in Parkinsons Disease
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Parkinson39s Disease PD and sarcopenia are prevalent age-related syndromes often occurring simultaneously within individuals Sarcopenia is notably common among PD patients with severe cases affecting approximately one in every five individuals with PD Moreover sarcopenia is closely linked to the accelerated progression of PD diminished quality of life heightened mortality risk and increased susceptibility to falls and fractures Therefore early detection of sarcopenia assumes particular significance as it offers an opportunity for interventions aimed at mitigating or delaying muscle degeneration potentially influencing PD outcomes This review will delve into the relationship between sarcopenia and PD methods for screening and testing sarcopenia and potential avenues for further research and the development of strategies for risk reduction and treatment
Detailed Description:
The onset of sarcopenia in PD may be intricately linked to both motor and non-motor symptoms In terms of motor symptoms sarcopenia exacerbates muscle weakness impairs balance and gait and may worsen symptoms like rigidity and bradykinesia in PD Numerous studies have shown that sarcopenia is strongly associated with disease duration Hoehn-Yahr staging and Unified PD Rating Scale-IIIUPDRSIII scores Regarding non-motor symptoms sarcopenia contributes to increased fatigue due to muscle weakness disrupts sleep patterns exacerbates psychological distress including depression and anxiety and may impact cognitive function In addition some studies supported that the incidence of falls disability and death in PD with Sarcopenia were higher than those in PD without sarcopenia
Nevertheless other studies have reported controversial results Some researchers believed that sarcopenia had no correlations with disease duration HY UPDRS-IIII cognition and depression However most of the current studies are small cross-sectional studies that are not very convincing about the relationship between diseases Thus further studies with long-term follow up and large sample sizes are required to determine the causal direction of these relationships
Nevertheless other studies have reported controversial results Some researchers believed that sarcopenia had no correlations with disease duration HY UPDRS-IIII cognition and depression However most of the current studies are small cross-sectional studies that are not very convincing about the relationship between diseases Thus further studies with long-term follow up and large sample sizes are required to determine the causal direction of these relationships
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None